Amid rapid shifts in medical innovation and investment structures, global venture capital is undergoing a strategic realignment. The 8th MEDTEX Forum has brought together six internationally influential biotech investment giants to share their perspectives on investment strategies and emerging opportunities in the AI era, making it one of the most closely watched international capital market events toward the end of the year.

Together, the six international funds featured at this year’s forum manage more than NT$8 trillion in capital, with cumulative investments in over 800 companies and more than 230 successful exits. Their portfolios span a wide range of fields, including AI-driven drug discovery, gene sequencing, and medical robotics.

Denmark-based NOVO Holdings, with assets under management of up to NT$4.8 trillion, is the world’s largest life sciences investment holding company and has built a global portfolio of 181 biotech companies.

Insight Partners, managing assets of approximately NT$2.7 trillion, will join five senior partners from Silicon Valley and other global innovation hubs to outline global investment opportunities for 2026.

Israel’s leading healthtech venture capital firm, aMoon Fund, is focusing on the transformative impact AI is bringing to biotechnology and healthcare.

Playground Global sees AI innovation in healthcare shifting from software toward “hard-tech integration,” while Illumina Ventures is targeting what it describes as a “second revolution” in gene sequencing, emphasizing AI’s ability to significantly accelerate analysis while reducing costs.

Ascenta Capital, which specializes in emerging biopharmaceuticals and technology platforms, is focusing on cross-regional venture capital strategies and new investment trends.

Allen Wu, Managing Director of Everbright Biofund, noted that this is no longer an era of going it alone. Taiwan’s biotech industry, he emphasized, cannot remain merely a follower but must become a “co-creator.” Over the next five years, if Taiwan is to secure a firm position in medical technology, it must co-invest with international venture capital, introduce AI-driven drug development and medical robotics technologies, position Taiwan as a combined clinical and manufacturing base, and build a cross-disciplinary talent pipeline—in order to compete successfully in the AI-led medical revolution.

This year’s MEDTEX Forum focuses on connecting top-tier international funds with Taiwanese capital, introducing technologies that have been vetted by global investors, and fostering co-creation models between Taiwan and international partners in Europe and the United States, enabling joint participation in the global arena.

Resource: 前瞻全球生醫創新：6生醫投資巨頭 齊聚MEDTEX